5 Stocks Boosting The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 30 points (-0.2%) at 15,089 as of Monday, May 13, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,245 issues advancing vs. 1,704 declining with 112 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is unchanged. Top gainers within the industry include St Jude Medical ( STJ), up 2.3%, Stryker Corporation ( SYK), up 0.8% and Zimmer Holdings ( ZMH), up 0.8%. On the negative front, top decliners within the industry include Agilent Technologies ( A), down 1.97, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.43 and Grifols ( GRFS), down 0.95.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Boston Scientific ( BSX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Boston Scientific is up $0.30 (3.55) to $8.75 on heavy volume Thus far, 18.4 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 18.2 million shares. The stock has ranged in price between $8.39-$8.84 after having opened the day at $8.40 as compared to the previous trading day's close of $8.45.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $11.2 billion and is part of the health care sector. Shares are up 44.9% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Boston Scientific Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways

Perils of Politics: Cramer's 'Mad Money' Recap (Monday 7/31/17)

These Stocks Are Ready to Reverse Course

Modi's Visit to Meet Trump Focuses Big Spotlight on the H-1B Visa Debate

Cramer: These Sectors Look Bullish (Part III)